Neuroscience
Biogen and Tokyo-based development partner Eisai are embroiled in controversy surrounding their investigational Alzheimer’s drug, aducanumab.
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
A study published in the Journal of the American Medical Association on July 29 now shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.
Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership has come to an end after AbbVie terminated the agreement.
A multi-omics, multi-algorithm approach will unleash a new wave of understanding around Alzheimer’s disease and diagnosis, that in time, will make precision diagnostics practical, speakers predicted at the Alzheimer’s Association International Conference 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AC Immune, based in Lausanne, Switzerland, initiated the second highest dosing group in its Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease. The move is based on encouraging interim data from the initial dosing cohort.
Diagnostics and therapeutics for Alzheimer’s disease are on the verge of becoming mainstream medicine. It’s about time, too.
The submission was completed with ongoing collaboration with the FDA and include data from the Phase III EMERGE and ENGAGE trials, as well as the Phase Ib PRIME study. Biogen has also requested Priority Review.
PRESS RELEASES